ArticleJournal of fungi (Basel, Switzerland)2025
Antifungal Susceptibilities of Rare Yeast Isolates.
Article in Journal of fungi (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Outbreak of Wickerhamomyces anomalus (formerly Candida pelliculosa) Bloodstream Infections, Venezuela, 2022-2023Emerging infectious diseases · 2026Article
- Urinary tract infection caused by rare yeastFrontiers in immunology · 2026Review
- A dual-phase strategy to integrate the VITEK MS RUO database into routine clinical practice: from validation of analytical performance to implementation of an automated workflow.Frontiers in cellular and infection microbiology · 2026Article
- Antifungal Susceptibility and Resistance-Associated Gene Expression in NosocomialJournal of fungi (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The recent increase in the number of rare yeasts isolated from clinical specimens is a cause for concern, requiring accurate identification of these yeasts and assessment of their antifungal susceptibility to guide treatment. In this regard, we identified 196 rare yeasts isolated from various clinical specimens, mostly urine and respiratory tract specimens of patients hospitalized in intensive care unit and wards, using MALDI-TOF MS, and assessed their susceptibility to amphotericin B, fluconazole, voriconazole, posaconazole, itraconazole, isavuconazole and anidulafungin using the EUCAST broth microdilution method. Among the rare yeast species we isolated,
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.